Abstract
Optimal identification of the risk of developing cardiotoxicity upon trastuzumab (TZM) treatment appears necessary as this risk may impair treatment compliance and compromise long-term recovery. To better understand and predict cardiac toxicity, the molecular mechanisms underlying this phenomenon need to be known. HER2 is present at the cell surface of cardiomyocytes. Neuregulin is produced by cardiac endothelial cells and binds to HER4, thus leading to dimerization with HER2 and subsequent cell signaling necessary for normal cardiac function. Decreasing HER2 activity has a major impact on cardiomyocyte function. However, the precise molecular mechanisms responsible for TZM-induced cardiac dysfunction are still unclear. This mini-review aims to summarize genetic, pharmacological and medical data helping to identify mechanisms that could explain cardiotoxicity. Of potential interest, these mechanisms highlight the importance of HER2 genetic polymorphism (Val655Ile) in the identification of patients at risk of developing TZMinduced cardiac effects.
Keywords: Cardiotoxicity, genetic polymorphism, HER2, personalized treatment, trastuzumab.
Graphical Abstract
Call for Papers in Thematic Issues
Emerging Drug Targets and Revolutionary Therapeutic Approaches for Effective Anti-Cancer Intervention
Recent advancements in cancer research have significantly advanced our understanding of the intricate molecular mechanisms driving cancer progression, leading to the identification of new drug targets and therapeutic strategies. The elucidation of complex signaling pathways and genetic aberrations associated with tumorigenesis has provided valuable insights into potential targets for intervention. ...read more
From Models to Molecules: Integrative Strategies in Herbal Product-based Drug Discovery
The toxic effects of synthetic drugs underscore the complex equilibrium between their therapeutic efficacy and the potential hazards they pose to biological systems. Natural products, with their diverse bioactive compounds and natural synergism, can help counteract synthetic drug toxicities by offering a complementary multi-targeted approach to mitigate organ damage and ...read more
Multitarget Agents For Complex Diseases
The basic principle of action of a drug is based on model lock and key, where is desirable the highest possible affinity for a target avoiding no side effects. For many years it was desirable‘one drug for one target for one disease’, however the researchers observed that complex diseases are ...read more
New Drug Therapy for Eye Diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Therapy
Current Drug Metabolism
Related Books
Brain Tumor Drug Development: Current Advances and Strategies (Part 1)
Handbook of Practical Pharmacology - I
Drug Repurposing for Antivirals
New Drugs Targeting Antibiotic-Resistant Bacteria: Recent Advances
Technical Advances in Pharmacy: An Overview
The Impact of Pharma Technology on Cosmetics: Advancements and Innovations
Advances in the Medicinal Chemistry of Neglected Tropical Disease and Related Infectious Diseases
Zebrafish Models for Experimental Pharmacology: A Handbook
Bioactive Compounds Targeting Neurodegenerative Diseases
Anthraquinones: Bioactive Multifaceted Therapeutic Agents
71